Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Flavin-containing monooxygenase, a new clue of pathological proteins in the rotenone model of parkinsonism.

Li B, Yuan Y, Zhang W, He W, Hu J, Chen N.

Neurosci Lett. 2014 Apr 30;566:11-6. doi: 10.1016/j.neulet.2013.11.036. Epub 2014 Jan 16.

PMID:
24440618
2.

N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: An investigation into the interaction of parkin and Drp1 proteins.

Rahimmi A, Khosrobakhsh F, Izadpanah E, Moloudi MR, Hassanzadeh K.

Brain Res Bull. 2015 Apr;113:34-40. doi: 10.1016/j.brainresbull.2015.02.007. Epub 2015 Feb 28.

PMID:
25732239
3.

Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.

Salama M, Ellaithy A, Helmy B, El-Gamal M, Tantawy D, Mohamed M, Sheashaa H, Sobh M, Arias-Carrión O.

CNS Neurol Disord Drug Targets. 2012 Nov 1;11(7):836-43.

PMID:
23198691
4.

Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat.

Sonia Angeline M, Chaterjee P, Anand K, Ambasta RK, Kumar P.

Neuroscience. 2012 Sep 18;220:291-301. doi: 10.1016/j.neuroscience.2012.06.021. Epub 2012 Jun 16.

PMID:
22710069
5.

α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.

George S, Mok SS, Nurjono M, Ayton S, Finkelstein DI, Masters CL, Li QX, Culvenor JG.

J Mol Neurosci. 2010 Oct;42(2):243-54. doi: 10.1007/s12031-010-9378-1. Epub 2010 May 13.

PMID:
20464527
6.

Inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of candesartan cilexitil in the rotenone rat model of Parkinson's disease.

Wu L, Tian YY, Shi JP, Xie W, Shi JQ, Lu J, Zhang YD.

Neurosci Lett. 2013 Aug 26;548:50-5. doi: 10.1016/j.neulet.2013.06.008. Epub 2013 Jun 14.

PMID:
23774475
7.

Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.

Jiang H, Ren Y, Zhao J, Feng J.

Hum Mol Genet. 2004 Aug 15;13(16):1745-54. Epub 2004 Jun 15.

8.

Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.

Moreira CG, Barbiero JK, Ariza D, Dombrowski PA, Sabioni P, Bortolanza M, Da Cunha C, Vital MA, Lima MM.

Neurotox Res. 2012 Apr;21(3):291-301. doi: 10.1007/s12640-011-9278-3. Epub 2011 Sep 28.

PMID:
21953489
9.

Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.

Inden M, Kitamura Y, Tamaki A, Yanagida T, Shibaike T, Yamamoto A, Takata K, Yasui H, Taira T, Ariga H, Taniguchi T.

Neurochem Int. 2009 Dec;55(8):760-7. doi: 10.1016/j.neuint.2009.07.009. Epub 2009 Aug 6.

PMID:
19647776
10.

Puerarin protects dopaminergic neurons in Parkinson's disease models.

Zhang X, Xiong J, Liu S, Wang L, Huang J, Liu L, Yang J, Zhang G, Guo K, Zhang Z, Wu P, Wang D, Lin Z, Xiong N, Wang T.

Neuroscience. 2014 Nov 7;280:88-98. doi: 10.1016/j.neuroscience.2014.08.052. Epub 2014 Sep 10.

PMID:
25218963
11.

Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.

Sherer TB, Kim JH, Betarbet R, Greenamyre JT.

Exp Neurol. 2003 Jan;179(1):9-16.

PMID:
12504863
12.

Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease.

Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, Goldberg AL, Liu JL, Isacson O, Tofaris GK.

Neurobiol Dis. 2014 Apr;64:79-87. doi: 10.1016/j.nbd.2013.12.011. Epub 2013 Dec 31.

13.

Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline.

Casarejos MJ, Menéndez J, Solano RM, Rodríguez-Navarro JA, García de Yébenes J, Mena MA.

J Neurochem. 2006 May;97(4):934-46. Epub 2006 Mar 29.

14.

bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease.

Xiong N, Yang H, Liu L, Xiong J, Zhang Z, Zhang X, Jia M, Huang J, Zhang Z, Mohamed AA, Lin Z, Wang T.

Environ Toxicol Pharmacol. 2013 Sep;36(2):411-22. doi: 10.1016/j.etap.2013.05.005. Epub 2013 May 22.

PMID:
23770451
15.

Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.

Norazit A, Meedeniya AC, Nguyen MN, Mackay-Sim A.

Brain Res. 2010 Nov 11;1360:119-29. doi: 10.1016/j.brainres.2010.08.070. Epub 2010 Aug 31.

PMID:
20807515
16.

A highly reproducible rotenone model of Parkinson's disease.

Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT.

Neurobiol Dis. 2009 May;34(2):279-90.

17.

Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.

Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, Sawada H, Izumi Y, Yamamoto N, Kihara T, Uemura K, Inoue H, Taniguchi T, Akaike A, Takahashi R, Shimohama S.

J Neurosci Res. 2009 Feb;87(2):576-85. doi: 10.1002/jnr.21869.

PMID:
18803299
18.

p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.

Wu F, Wang Z, Gu JH, Ge JB, Liang ZQ, Qin ZH.

Neurochem Int. 2013 Sep;63(3):133-40. doi: 10.1016/j.neuint.2013.05.006. Epub 2013 May 25.

PMID:
23714208
19.

Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression.

Benskey M, Behrouz B, Sunryd J, Pappas SS, Baek SH, Huebner M, Lookingland KJ, Goudreau JL.

Neurotoxicology. 2012 Jun;33(3):321-31. doi: 10.1016/j.neuro.2012.02.001. Epub 2012 Feb 9. Erratum in: Neurotoxicology. 2012 Jun;33(3):406.

20.

Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease.

Wu F, Xu HD, Guan JJ, Hou YS, Gu JH, Zhen XC, Qin ZH.

Neuroscience. 2015 Jan 22;284:900-11. doi: 10.1016/j.neuroscience.2014.11.004. Epub 2014 Nov 13.

PMID:
25446361
Items per page

Supplemental Content

Write to the Help Desk